Intra-Cellular Therapies, Inc., a leading biopharmaceutical company based in the United States, focuses on developing innovative treatments for neuropsychiatric diseases. Founded in 2002, the company has made significant strides in the industry, particularly with its flagship product, Caplyta (lumateperone), which has garnered attention for its unique mechanism of action in treating schizophrenia and bipolar depression. With a strong presence in the US and expanding operations in key global markets, Intra-Cellular Therapies is committed to addressing unmet medical needs through its cutting-edge research and development efforts. The company’s dedication to advancing mental health therapies positions it as a notable player in the biopharmaceutical landscape, with a focus on improving patient outcomes and enhancing quality of life.
We don't have data for Intra-Cellular Therapies, Inc., but we can show you information about their parent organization instead.
View parent company